Feature Healthcare Stocks Cardiol Therapeutics: Analysts and Institutions Are In Ahead of the pivotal Phase III MAVERIC topline results, expected in mid-2027,… Robin LeffertsSeptember 24, 2026
Feature Healthcare Stocks Top News Pivotal Phase III Pericarditis Trial Expanding Across United States Cardiol Therapeutics (Nasdaq: CRDL) (TSX: CRDL) is conducting a Phase III clinical… Robin LeffertsMay 20, 2026
Healthcare Stocks Cardiol Therapeutics’ Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association Results demonstrate CardiolRx™ may represent a paradigm shift in the treatment of… Ryan AllwayMay 7, 2026
Feature Healthcare Stocks Top News Monte Rosa’s Big Raise Shows Why Anti-Inflammatory Stories Are in Focus Eli Lilly’s buyout of Ventyx Biosciences (Nasdaq: VTYX) signaled that Big Pharma… Robin LeffertsJanuary 28, 2026
Feature Healthcare Stocks Top News Ventyx/Lilly Deal Shows the Value of Anti-inflammatory Drugs We wrote late last year about the recent upswing in big pharma… Robin LeffertsJanuary 15, 2026
Feature Healthcare Stocks Top News A Close Look at Cardiol Therapeutics’ Phase 2 Results Shows the Path Forward Not all clinical trial results are cut and dried. Sometimes the outcome… Robin LeffertsDecember 9, 2025
Feature Healthcare Stocks Top News Investor Opportunity: Big Pharma Patent Cliff Spurring Surge in M&A Activity Here’s the short version: Big pharma is staring down a real patent… Robin LeffertsNovember 18, 2025
Feature Healthcare Stocks The Growing Market for Recurrent Pericarditis Therapies Recurrent pericarditis management has evolved significantly in recent years, with treatment approaches… Robin LeffertsApril 16, 2025
Healthcare Stocks Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis Toronto, Ontario–(Newsfile Corp. – April 16, 2025) – Cardiol Therapeutics Inc. (NASDAQ: CRDL)… Ryan AllwayApril 16, 2025
Feature Healthcare Stocks From $1 to $8? Why Analyst Experts Are Bullish on Cardiol Sometimes stock market performance doesn’t line up with the fundamentals of a… Robin LeffertsApril 1, 2025
